Herantis Pharma (Finland)

CDNF Protein Therapy in Parkinson’s Disease

Henri J. Huttunen, Märt Saarma · Cell Transplantation · 2019 · 86 citations · Full text

Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo

Katrina Albert, Diana Pelizzari Raymundo, Anne Panhelainen et al. · Molecular Therapy · 2021 · 44 citations · Full text

Intrastriatally Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra

Kert Mätlik, Helena Vihinen, Ali Bienemann et al. · eNeuro · 2017 · 38 citations · Full text

Augmenting hematoma-scavenging capacity of innate immune cells by CDNF reduces brain injury and promotes functional recovery after intracerebral hemorrhage

Kuan-Yin Tseng, Vassilis Stratoulias, Wei-Fen Hu et al. · Cell Death and Disease · 2023 · 34 citations · Full text

Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema

Ida-Maria Leppäpuska, Pauliina Hartiala, Sinikka Suominen et al. · Journal of Plastic Reconstructive & Aesthetic Surgery · 2022 · 33 citations · Full text